REAL-WORLD ECONOMIC ANALYSIS OF FIXED-DURATION VENETOCLAX-BASED VERSUS CONTINUOUS BTKI THERAPY IN FIRST-LINE CHRONIC LYMPHOCYTIC LEUKEMIA IN GREECE
Author(s)
Charalampos Tzanetakos, MSc1, GEORGIOS PAPAGEORGIOU, MSc2, Aikaterini Kollia, MSc3, Aristeidis Draganigos, MSc3, Thanasis Vlachopiotis, MSc3, George Gourzoulidis, PhD1.
1Health Through Evidence, Athens, Greece, 2AbbVie Hellas,, Athens, Greece, 3AbbVie Hellas, Athens, Greece.
1Health Through Evidence, Athens, Greece, 2AbbVie Hellas,, Athens, Greece, 3AbbVie Hellas, Athens, Greece.
OBJECTIVES: To evaluate the economic impact and cost per responder of fixed-duration venetoclax-based therapy compared with continuous BTK inhibitor (BTKi) regimens in previously untreated chronic lymphocytic leukemia (CLL) patients in Greece.
METHODS: A de novo economic model was developed using aggregated retrospective real-world data from a project-based Greek database (hosted in CERTH)) from 165 patients between 2021 and 2025, reflecting treatment patterns and clinical outcomes of first-line CLL patients treated in routine clinical practice in Greece. The analysis compared a current practice scenario with observed uptake of venetoclax- and BTKi-based therapies to a projected scenario with expanded use of fixed-duration venetoclax-based regimens among eligible patients, excluding those with del(17p) in line with ESMO recommendations. Analyses were conducted over a five-year time horizon from the payer perspective. Drug acquisition costs were considered in the analysis. Key outcomes included total budget impact and cost per responder (CR/CRi), derived directly from real-world response rates.
RESULTS: Under current clinical practice, the cumulative five-year budget impact amounted to €7,235,965. In the projected scenario with greater adoption of fixed-duration venetoclax-based therapy, total expenditure decreased to €4,390,224, resulting in absolute five-year cost savings of €2,845,741, corresponding to a 39% reduction in total budget impact. Real-world clinical outcomes demonstrated higher CR/CRi rates with venetoclax-based regimens compared with BTKi-based therapy (72% vs 20%). Correspondingly, the cost per CR/CRi responder was approximately three-fold higher with BTKi-based regimens compared with venetoclax-based therapy (€102,994 vs €36,954), indicating substantially higher costs required to achieve response with continuous treatment strategies.
CONCLUSIONS: Using Greek real-world data, fixed-duration venetoclax-based therapy in first-line CLL was associated with substantial budget savings and a markedly lower cost per responder compared with continuous BTKi therapy. These findings suggest that fixed-duration venetoclax-based regimens may represent a more economically sustainable treatment strategy, improving payer efficiency while maintaining favorable clinical outcomes in routine practice.
METHODS: A de novo economic model was developed using aggregated retrospective real-world data from a project-based Greek database (hosted in CERTH)) from 165 patients between 2021 and 2025, reflecting treatment patterns and clinical outcomes of first-line CLL patients treated in routine clinical practice in Greece. The analysis compared a current practice scenario with observed uptake of venetoclax- and BTKi-based therapies to a projected scenario with expanded use of fixed-duration venetoclax-based regimens among eligible patients, excluding those with del(17p) in line with ESMO recommendations. Analyses were conducted over a five-year time horizon from the payer perspective. Drug acquisition costs were considered in the analysis. Key outcomes included total budget impact and cost per responder (CR/CRi), derived directly from real-world response rates.
RESULTS: Under current clinical practice, the cumulative five-year budget impact amounted to €7,235,965. In the projected scenario with greater adoption of fixed-duration venetoclax-based therapy, total expenditure decreased to €4,390,224, resulting in absolute five-year cost savings of €2,845,741, corresponding to a 39% reduction in total budget impact. Real-world clinical outcomes demonstrated higher CR/CRi rates with venetoclax-based regimens compared with BTKi-based therapy (72% vs 20%). Correspondingly, the cost per CR/CRi responder was approximately three-fold higher with BTKi-based regimens compared with venetoclax-based therapy (€102,994 vs €36,954), indicating substantially higher costs required to achieve response with continuous treatment strategies.
CONCLUSIONS: Using Greek real-world data, fixed-duration venetoclax-based therapy in first-line CLL was associated with substantial budget savings and a markedly lower cost per responder compared with continuous BTKi therapy. These findings suggest that fixed-duration venetoclax-based regimens may represent a more economically sustainable treatment strategy, improving payer efficiency while maintaining favorable clinical outcomes in routine practice.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EPH182
Topic
Economic Evaluation, Epidemiology & Public Health, Real World Data & Information Systems
Topic Subcategory
Public Health
Disease
Oncology